Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage2021 · 52 citations
2. 2SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma2020 · 281 citations
3. 3Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report2020 · 38 citations
4. 4Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients2020 · 85 citations
5. 5Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding2020 · 2,272 citations